US equities |
MU $884.96 ▼-3.19% NVDA $215.87 ▼-2.46% SNDK $1,312.59 ▼-6.47% SPCX $145.65 ▼-4.28% AMD $536.27 ▼-6.05% INTC $92.14 ▼-6.09% TSM $413.40 ▼-3.86% AAPL $344.82 ▲+0.54%
FinancialContent

Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

1.944 -0.026 (-1.35%)
Delayed Quote Updated: 9:58 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Polaryx Therapeutics, Inc. - Common Stock

News headline image
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Polaryx Therapeutics Stock Is Surging On Thursday? ↗
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders. 
Via Benzinga
News headline image
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
Tuesday's session: top gainers and losers ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day. 
Via Stocktwits
Topics ETFs
News headline image
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's Going On With Polaryx Therapeutics Stock Wednesday? ↗
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement. 
Via Benzinga
News headline image
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans ↗
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders. 
Via Benzinga
News headline image
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil) 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Welcomes New Members of the Board of Directors
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug... 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire